Clinical Trial Update: Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing aliskiren 300 mg with irbesartan 300 mg and ramipril 10 mg in adults with essential hypertension, examining efficacy and safety in the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Aliskiren (Aliskiren)
• Irbesartan (irbesartan)
• Ramipril (ramipril)

Snippet

Sponsor: Novartis | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED